Business1h agoAsianet Newsable

Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document

in5points

FDA briefing documents raised concerns about Deramiocel's effectiveness for cardiomyopathy in Duchenne muscular dystrophy patients.
Capricor CEO claims FDA used 'obsolete' analysis in the review process.
CAPR stock price dropped following the release of the FDA briefing document.

Story angle

Center-right

Mostly straight facts, with a light government- or market-friendly tilt.

About how the story is framed, not whether the facts are true.

Center-right

Mixed factuality

Who owns this?

Asianet News Network

Rajeev Chandrasekhar / Jupiter Capital interests historically

Left blind spot

Only right-leaning outlets are covering this so far.

Outlet lean

1 source

Left

Center

Right

Compare headlines

Same story, different framing

CenterAsianet Newsable
CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote
The article frames the FDA briefing as casting doubt on Deramiocel's efficacy, focusing on the negative impact on Capricor's stock price.
RightAsianet Newsable
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
The headline emphasizes Capricor's accusation against the FDA and the resulting stock drop, framing the story from a business and corporate perspective.

›

2 outlets